"The U.S. Food and Drug Administration today approved Viberzi (eluxadoline) and Xifaxan (rifaximin), two new treatments, manufactured by two different companies, for irritable bowel syndrome with diarrhea (IBS-D) in adult men and women.
Levsin® (hyoscyamine) inhibits specifically the actions of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These peripheral cholinergic receptors are present in the autonomic effector cells of the smooth muscle, cardiac muscle, the sinoatrial node, the atrioventricular node, and the exocrine glands. At therapeutic doses, it is completely devoid of any action on autonomic ganglia. Levsin® (hyoscyamine) inhibits gastrointestinal propulsive motility and decreases gastric acid secretion. Levsin® (hyoscyamine) also controls excessive pharyngeal, tracheal and bronchial secretions.
Levsin® (hyoscyamine) is absorbed totally and completely by sublingual administration as well as oral administration. Once absorbed, Levsin® (hyoscyamine) disappears rapidly from the blood and is distributed throughout the entire body. The half-life of Levsin® (hyoscyamine) is 2 to 3½ hours. Levsin® (hyoscyamine) is partly hydrolyzed to tropic acid and tropine but the majority of the drug is excreted in the urine unchanged within the first 12 hours. Only traces of this drug are found in breast milk. Levsin® (hyoscyamine) passes the blood brain barrier and the placental barrier.
Last reviewed on RxList: 11/17/2010
This monograph has been modified to include the generic and brand name in many instances.
Additional Levsin Information
Levsin - User Reviews
Levsin User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.